Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

318 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer's disease.
Lozupone M, Dibello V, Sardone R, Castellana F, Zupo R, Lampignano L, Bortone I, Stallone R, Altamura M, Bellomo A, Daniele A, Solfrizzi V, Panza F. Lozupone M, et al. Among authors: solfrizzi v. Expert Opin Drug Discov. 2024 Jun;19(6):639-647. doi: 10.1080/17460441.2024.2348142. Epub 2024 Apr 29. Expert Opin Drug Discov. 2024. PMID: 38685682 Review.
The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset.
Panza F, Seripa D, Lozupone M, Solfrizzi V, Imbimbo BP, Barulli MR, Tortelli R, Capozzo R, Bisceglia P, Dimitri A, Stallone R, Dibello V, Quaranta N, Daniele A, Bellomo A, Greco A, Logroscino G. Panza F, et al. Among authors: solfrizzi v. Expert Opin Biol Ther. 2018 Jan;18(1):25-35. doi: 10.1080/14712598.2018.1389885. Epub 2017 Oct 16. Expert Opin Biol Ther. 2018. PMID: 29037101 Review.
Pharmacotherapy for the treatment of depression in patients with alzheimer's disease: a treatment-resistant depressive disorder.
Lozupone M, La Montagna M, D'Urso F, Piccininni C, Sardone R, Dibello V, Giannelli G, Solfrizzi V, Greco A, Daniele A, Quaranta N, Seripa D, Bellomo A, Logroscino G, Panza F. Lozupone M, et al. Among authors: solfrizzi v. Expert Opin Pharmacother. 2018 Jun;19(8):823-842. doi: 10.1080/14656566.2018.1471136. Epub 2018 May 4. Expert Opin Pharmacother. 2018. PMID: 29726758 Review.
BACE inhibitors in clinical development for the treatment of Alzheimer's disease.
Panza F, Lozupone M, Solfrizzi V, Sardone R, Piccininni C, Dibello V, Stallone R, Giannelli G, Bellomo A, Greco A, Daniele A, Seripa D, Logroscino G, Imbimbo BP. Panza F, et al. Among authors: solfrizzi v. Expert Rev Neurother. 2018 Nov;18(11):847-857. doi: 10.1080/14737175.2018.1531706. Epub 2018 Oct 24. Expert Rev Neurother. 2018. PMID: 30277096
ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer's disease.
Lozupone M, Berardino G, Mollica A, Sardone R, Dibello V, Zupo R, Lampignano L, Castellana F, Bortone I, Stallone R, Daniele A, Altamura M, Bellomo A, Solfrizzi V, Panza F. Lozupone M, et al. Among authors: solfrizzi v. Expert Opin Investig Drugs. 2022 Aug;31(8):759-771. doi: 10.1080/13543784.2022.2095261. Epub 2022 Jun 29. Expert Opin Investig Drugs. 2022. PMID: 35758153 Review.
The development of peptide- and oligonucleotide-based drugs to prevent the formation of abnormal tau in tauopathies.
Lozupone M, Dibello V, Sardone R, Castellana F, Zupo R, Lampignano L, Bortone I, Stallone R, Altamura M, Bellomo A, Daniele A, Solfrizzi V, Panza F. Lozupone M, et al. Among authors: solfrizzi v. Expert Opin Drug Discov. 2023 May;18(5):515-526. doi: 10.1080/17460441.2023.2200245. Epub 2023 Apr 11. Expert Opin Drug Discov. 2023. PMID: 37042028 Review.
Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies.
Panza F, Dibello V, Sardone R, Castellana F, Zupo R, Lampignano L, Bortone I, Stallone R, Cirillo N, Damiani C, Altamura M, Bellomo A, Daniele A, Solfrizzi V, Lozupone M. Panza F, et al. Among authors: solfrizzi v. Expert Opin Investig Drugs. 2023 Jul-Dec;32(7):625-634. doi: 10.1080/13543784.2023.2233892. Epub 2023 Jul 10. Expert Opin Investig Drugs. 2023. PMID: 37405389 Review.
318 results